用于治疗良性前列腺增生的α受体阻滞剂。
Alpha blockers for the treatment of benign prostatic hyperplasia.
作者信息
Lepor Herbert
机构信息
Department of Urology, New York University School of Medicine New York, NY.
出版信息
Rev Urol. 2007 Fall;9(4):181-90.
Abstract
The evolution of alpha blocker therapy for benign prostatic hyperplasia (BPH) has focused on improving convenience and tolerability. Indications for treating BPH include reversing signs and symptoms or preventing progression of the disease. The indication that most commonly drives the need for intervention is relief of lower urinary tract symptoms (LUTS) with the intent of improving quality of life. Alpha blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Four long-acting alpha 1 blockers are approved by the Food and Drug Administration for treatment of symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, and alfuzosin. All are well tolerated and have comparable dose-dependent effectiveness. Tamsulosin and alfuzosin SR do not require dose titration. Alfuzosin, terazosin, and doxazosin have all been shown to be effective in relieving LUTS/BPH independent of prostate size.
摘要
用于良性前列腺增生（BPH）的α受体阻滞剂疗法的发展一直专注于提高便利性和耐受性。治疗BPH的适应症包括逆转体征和症状或预防疾病进展。最常促使进行干预的适应症是缓解下尿路症状（LUTS），目的是改善生活质量。α受体阻滞剂是缓解LUTS最有效、成本最低且耐受性最佳的药物。四种长效α1受体阻滞剂已获美国食品药品监督管理局批准用于治疗有症状的LUTS/BPH：特拉唑嗪、多沙唑嗪、坦索罗辛和阿夫唑嗪。所有这些药物耐受性良好，且具有相当的剂量依赖性疗效。坦索罗辛和缓释阿夫唑嗪不需要剂量滴定。已证明阿夫唑嗪、特拉唑嗪和多沙唑嗪在缓解LUTS/BPH方面有效，且与前列腺大小无关。
相似文献
1
Alpha blockers for the treatment of benign prostatic hyperplasia.
Rev Urol. 2007 Fall;9(4):181-90.
2
α-Blockers for benign prostatic hyperplasia: the new era.
Curr Opin Urol. 2012 Jan;22(1):7-15. doi: 10.1097/MOU.0b013e32834d9bfd.
3
The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia.
Rev Urol. 2006;8 Suppl 4(Suppl 4):S3-9.
4
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Eur Urol. 1999;36(1):1-13. doi: 10.1159/000019919.
5
A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
Indian J Pharmacol. 2016 Mar-Apr;48(2):134-40. doi: 10.4103/0253-7613.178825.
6
The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
Clin Drug Investig. 2015 Feb;35 Suppl 1:7-18. doi: 10.1007/s40261-014-0257-3.
7
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
JAMA Neurol. 2021 Apr 1;78(4):407-413. doi: 10.1001/jamaneurol.2020.5157.
8
The role of combination medical therapy in benign prostatic hyperplasia.
Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51.
9
Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.
Rev Urol. 2009 Fall;11(Suppl 1):S1-8.
10
Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis.
Ther Adv Urol. 2021 Apr 12;13:1756287221993283. doi: 10.1177/1756287221993283. eCollection 2021 Jan-Dec.
引用本文的文献
1
The combination of water extracts of Radix and Flos improves benign prostatic hyperplasia by suppressing testosterone-induced proliferation of prostate cells and .
Nutr Res Pract. 2025 Jun;19(3):345-360. doi: 10.4162/nrp.2025.19.3.345. Epub 2024 Dec 9.
2
Molecular mechanism of antagonist recognition and regulation of the α-adrenoceptor.
J Biol Chem. 2025 Jun 6;301(7):110348. doi: 10.1016/j.jbc.2025.110348.
3
Identifying progression subphenotypes of Alzheimer's disease from large-scale electronic health records with machine learning.
J Biomed Inform. 2025 May;165:104820. doi: 10.1016/j.jbi.2025.104820. Epub 2025 Apr 1.
4
Falls in a single brain rehabilitation center: a 3-year retrospective chart review.
Front Neurol. 2025 Feb 24;16:1519555. doi: 10.3389/fneur.2025.1519555. eCollection 2025.
5
Administering prophylactic alpha-blockade to reduce urinary retention post inguinal hernia repair: A systematic review and meta-analysis of randomised control trials.
Surg Pract Sci. 2023 Jul 29;14:100204. doi: 10.1016/j.sipas.2023.100204. eCollection 2023 Sep.
6
Alpha-1 antagonist treatment for eyelid retraction in patients with thyroid eye disease-a prospective pilot study.
Eye (Lond). 2025 Jan;39(1):175-178. doi: 10.1038/s41433-024-03403-8. Epub 2024 Oct 21.
7
Bioassay-guided isolation of two antiproliferative metabolites from Willd. against TGF-β-induced prostate stromal cells (WPMY-1) proliferation via PI3K/AKT signaling pathway.
Front Pharmacol. 2024 Oct 3;15:1452887. doi: 10.3389/fphar.2024.1452887. eCollection 2024.
8
Tamsulosin use in benign prostatic hyperplasia and risks of Parkinson's disease, Alzheimer's disease and mortality: An observational cohort study of elderly Medicare enrollees.
PLoS One. 2024 Aug 22;19(8):e0309222. doi: 10.1371/journal.pone.0309222. eCollection 2024.
9
Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists.
J Natl Cancer Inst. 2024 Sep 1;116(9):1459-1465. doi: 10.1093/jnci/djae108.
10
Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions.
J Pharmacol Exp Ther. 2024 Jul 18;390(2):222-232. doi: 10.1124/jpet.123.002081.
本文引用的文献
1
Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.
Rev Urol. 2007 Spring;9(2):73-7.
2
Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
J Urol. 2007 Aug;178(2):395-401. doi: 10.1016/j.juro.2007.03.103. Epub 2007 Jun 11.
3
Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction.
Urology. 2007 May;69(5):805-9. doi: 10.1016/j.urology.2007.02.036.
4
Current concepts in ejaculatory dysfunction.
Rev Urol. 2006;8 Suppl 4(Suppl 4):S18-25.
5
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
JAMA. 2006 Nov 15;296(19):2319-28. doi: 10.1001/jama.296.19.2319.
6
Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers.
J Urol. 2006 Oct;176(4 Pt 1):1529-33. doi: 10.1016/j.juro.2006.06.004.
7
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
BJU Int. 2006 Apr;97(4):734-41. doi: 10.1111/j.1464-410X.2006.06110.x.
8
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
J Urol. 2006 Jan;175(1):217-20; discussion 220-1. doi: 10.1016/S0022-5347(05)00041-8.
9
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Urology. 2005 Jan;65(1):83-9; discussion 89-90. doi: 10.1016/j.urology.2004.07.042.
10
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
N Engl J Med. 2003 Dec 18;349(25):2387-98. doi: 10.1056/NEJMoa030656.
Zotero 插件